Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis
JCO Global Oncology · 2026
DOI: 10.1200/go-24-00435 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Jing Yang und 26 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Col…. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Combined-modality therapy (CMT) improves survival in patients with early-stage extranodal natural killer-/T-cell lymphoma (ENKTCL) compared with radiotherapy (RT) alone. However, the effect is inadequate for low-risk patients as defined by nomogram-revised risk index (NRI). As such, it remains unclear whether the survival benefits outweigh the additional costs. MATERIALS AND METHODS A Markov model was constructed to compare CMT versus RT alone for patients with early-stage ENKTCL, according to five risk groups defined by NRI model. Transition probabilities, effectiveness, and cost data were derived from the China Lymphoma Collaborative Group cohort, while health utility data were estimated from adverse effects. Life-years, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios were calculated from the perspective of Chinese payers. Evaluations for customized countries or settings can be accomplished using a web-based tool. RESULTS Over the 6-year horizon, CMT increased life-years by 5.47, 5.19, 4.82, 4.62, and 4.49 years at $517,472 US dollars (USD)/QALY, $22,871 USD/QALY, $7,865 USD/QALY, $4,598 USD/QALY, and $2,278 USD/QALY for the low-risk (NRI = 0), intermediate-low-risk (NRI = 1), intermediate-high-risk (NRI = 2), high-risk (NRI = 3), and very high-risk (NRI = 4) groups, respectively. The probabilities of cost-effectiveness at a willingness-to-pay threshold of $5,208 USD/QALY were 0.00%, 0.01%, 7.40%, 72.07%, and 99.10% for each risk group. Over the lifetime horizon, all risk groups, except for low-risk group, had a probability of over 90% of being cost-effective. Estimates were varied according to country settings, integrated through a web-based customized analysis. CONCLUSION CMT is unlikely to be cost-effective for low-risk patients but highly likely to be cost-effective for high-risk and very high-risk patients. As for intermediate-low or intermediate-high-risk patients, the cost-effectiveness of CMT varies depending on the time horizon and willingness-to-pay threshold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Beijing Hospital, National Geriatric Medical Center, Beijing, China.
- The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Qiu-Zi Zhong, Yong Yang, Xiao-Rong Hou, Xi-Mei Zhang, Yu-Qin Song, Jun Zhu, Hui-Qiang Huang, Ying Wang, Shu-Nan Qi, Ye-Xiong Li
Zitieren
APA
Yang, J., Zhong, Q. Z., Qian, L. T., Yang, Y., Hou, X. R., Qiao, X. Y., Wang, H., Zhu, Y., Cao, J. Z., Wu, J. X., Wu, T., Zhu, S. Y., Shi, M., Zhang, H. L., Zhang, X. M., Su, H., Song, Y. Q., Zhu, J., Zhang, Y. J., …, & Li, Y. X. (2026). Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis. JCO Global Oncology. https://doi.org/10.1200/go-24-00435
Vancouver
Yang J, Zhong QZ, Qian LT, Yang Y, Hou XR, Qiao XY, et al. Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis. JCO Global Oncology. 2026. doi:10.1200/go-24-00435
BibTeX
@article{Yang2026,
author = {Yang, Jing and Zhong, Qiu-Zi and Qian, Li-Ting and Yang, Yong and Hou, Xiao-Rong and Qiao, Xue-Ying and Wang, Hua and Zhu, Yuan and Cao, Jian-Zhong and Wu, Jun-Xin and Wu, Tao and Zhu, Su-Yu and Shi, Mei and Zhang, Hui-Lai and Zhang, Xi-Mei and Su, Hang and Song, Yu-Qin and Zhu, Jun and Zhang, Yu-Jing and Huang, Hui-Qiang and Wang, Ying and He, Xia and Zhang, Li-Ling and Wang, Shu-Lian and Qi, Shu-Nan and Qu, Bao-Lin and Li, Ye-Xiong},
title = {Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis},
journal = {JCO Global Oncology},
year = {2026},
doi = {10.1200/go-24-00435}
}
EUVIMED